APA (7th ed.) Citation

KL, C., SW, H., JJ, Y., SW, H., S, G., XR, T., . . . N, L. (2024). LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 76, 101111. https://doi.org/10.1016/j.drup.2024.101111

Chicago Style (17th ed.) Citation

KL, Chen, et al. "LncRNA DYNLRB2-AS1 Promotes Gemcitabine Resistance of Nasopharyngeal Carcinoma by Inhibiting the Ubiquitination Degradation of DHX9 Protein." Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy 76 (2024): 101111. https://doi.org/10.1016/j.drup.2024.101111.

MLA (9th ed.) Citation

KL, Chen, et al. "LncRNA DYNLRB2-AS1 Promotes Gemcitabine Resistance of Nasopharyngeal Carcinoma by Inhibiting the Ubiquitination Degradation of DHX9 Protein." Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, vol. 76, 2024, p. 101111, https://doi.org/10.1016/j.drup.2024.101111.